<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Vet. Sci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Veterinary Science</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Vet. Sci.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2297-1769</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fvets.2025.1652991</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Establishment and characterization of primary epithelial cell cultures from healthy canine mammary gland tissue</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nosalova</surname>
<given-names>Natalia</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3109826"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huniadi</surname>
<given-names>Mykhailo</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2933790"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valencakova</surname>
<given-names>Alexanda</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hornakova</surname>
<given-names>Lubica</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3190560"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalinaj</surname>
<given-names>Blazej</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almasiova</surname>
<given-names>Viera</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2914891"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marcincakova</surname>
<given-names>Dana</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2913021"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kubatka</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hornak</surname>
<given-names>Slavomir</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cizkova</surname>
<given-names>Dasa</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/945974"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Small Animal Clinic, University of Veterinary Medicine and Pharmacy in Ko&#x0161;ice</institution>, <city>Ko&#x0161;ice</city>, <country country="sk">Slovakia</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Anatomy, Histology and Physiology, University of Veterinary Medicine and Pharmacy in Ko&#x0161;ice</institution>, <city>Ko&#x0161;ice</city>, <country country="sk">Slovakia</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Pharmacology and Toxicology, University of Veterinary Medicine and Pharmacy in Ko&#x0161;ice</institution>, <city>Ko&#x0161;ice</city>, <country country="sk">Slovakia</country></aff>
<aff id="aff4"><label>4</label><institution>Institute of Neuroimmunology, SAS</institution>, <city>Bratislava</city>, <country country="sk">Slovakia</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Dasa Cizkova, <email xlink:href="mailto:dasa.cizkova@uvlf.sk">dasa.cizkova@uvlf.sk</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-28">
<day>28</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>12</volume>
<elocation-id>1652991</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>08</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Nosalova, Huniadi, Valencakova, Hornakova, Kalinaj, Almasiova, Marcincakova, Kubatka, Hornak and Cizkova.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Nosalova, Huniadi, Valencakova, Hornakova, Kalinaj, Almasiova, Marcincakova, Kubatka, Hornak and Cizkova</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-28">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>In regenerative medicine and comparative oncology, the development of physiologically relevant in vitro models is critical for advancing our understanding of tissue homeostasis, cellular differentiation, and early tumorigenesis. Such models provide controlled experimental systems to investigate normal mammary gland function, assess responses to therapeutic agents, and establish baseline characteristics for distinguishing healthy from pathological tissue.</p>
</sec>
<sec>
<title>Methods</title>
<p>This study successfully established and characterized primary epithelial cell cultures derived from histologically normal canine mammary gland (CMG) tissue. Samples from two healthy female dogs were obtained during elective ovariohysterectomy. Following enzymatic digestion and optimized culture conditions, isolated cells adhered within 24 hours and reached confluence within 6&#x2013;7 days, maintaining over 95% viability.</p>
</sec>
<sec>
<title>Results and discussion</title>
<p>Histological analysis confirmed either active lactational or regressive tissue states. Cell growth and metabolic activity were evaluated using the CELLigence system and XTT assay, with optimal results achieved at a seeding density of 4,000 cells per well. Immunofluorescence staining confirmed epithelial identity (pan-CK, CK8/18), apical MUC1 expression, low Ki-67 levels and negative expression of mesenchymal markers (vimentin, S100), indicating a healthy, non-cancerous cell population with moderate proliferative activity. This study provides the first detailed protocol for establishing primary CMG epithelial cultures and validates their suitability as a reference model for future oncological studies. Overall, this platform supports translational research, including drug testing and biomarker discovery, contributes to personalized veterinary therapies and enhanced understanding of mammary gland pathology in both dogs and humans.</p>
</sec>
</abstract>
<kwd-group>
<kwd>biomarkers</kwd>
<kwd>canine mammary gland</kwd>
<kwd>histology</kwd>
<kwd>isolation of cells</kwd>
<kwd>oncology</kwd>
<kwd>primary cell cultures</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by APVV-24-0026 (NN), VEGA 1/0236/23 (VA) and VEGA 1/0122/24 (DC).</funding-statement>
</funding-group>
<counts>
<fig-count count="10"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="67"/>
<page-count count="14"/>
<word-count count="9611"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Oncology in Veterinary Medicine</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>The active mammary gland is a compound, tubuloalveolar gland found only in mammals, designed to feed the offspring and support its immune system (<xref ref-type="bibr" rid="ref1">1</xref>). Glandular parenchyma consists of alveoli and ductal structures organized into lobules, which are surrounded by connective tissue septa. The ductal system begins with an intralobular duct, which drains into an interlobular duct and finally into lactiferous ducts. Several lactiferous ducts drain into a lactiferous sinus, which joins the teat sinus (<xref ref-type="bibr" rid="ref2">2</xref>). The mammary gland is highly dependent on hormonal stimulation, and its development and action are controlled by various hormones (prolactin, estrogen, and progesterone). The mammary gland is also strongly influenced by the estrous cycle and pregnancy (<xref ref-type="bibr" rid="ref1">1</xref>). The mammary gland of women and dogs share similar morphological characteristics, differing in the number of glandular units, number of nipples/teats, hormonal regulation, functional cycles and milk composition. In dogs, four to six pairs of glands have been described, with the inguinal pairs being the largest, the abdominal pairs intermediate, and the thoracic pairs the smallest in size (<xref ref-type="bibr" rid="ref1">1</xref>).</p>
<p>Due to the constantly increasing number of cases and the clinical significance of breast cancer (BC), research into physiology and pathology of mammary glands has increased significantly. In this context, female dogs have emerged as valuable comparative animal models for studying human cancer, providing samples for the development of alternative <italic>in vitro</italic> models and playing a key role in advancing progress in this research area (<xref ref-type="bibr" rid="ref3">3</xref>). Building on tissue-derived cell cultures, established cell lines play a fundamental role in research for their importance in the study of diseases, stem and cancer cells investigation, drug discovery, and the establishment of new therapies (<xref ref-type="bibr" rid="ref4">4</xref>). Even though immortalized cell lines are widely employed in biomedical research because of their reproducibility and ease of maintenance, they often differ greatly from <italic>in vivo</italic> cells, exhibiting altered gene expression profiles and the loss of tissue-specific functions (<xref ref-type="bibr" rid="ref5">5</xref>). For these reasons, primary cell cultures isolated from tissues are becoming more widely acknowledged as more physiologically relevant models in molecular biology, oncology and pharmacological research (<xref ref-type="bibr" rid="ref6">6</xref>). Furthermore, they serve as an excellent preclinical model essential for studying gene expression, modification of signaling pathways, oncogene activation, and the development of new drugs and therapeutic strategies (<xref ref-type="bibr" rid="ref7">7</xref>). Several cell types can be isolated from the canine mammary gland, including epithelial cells, myoepithelial cells, stromal fibroblasts, adipocytes, mesenchymal stem cells (MSCs), and resident immune cells (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref3">3</xref>, <xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). Among these, primary cultures of mammary epithelial cells are the most commonly used in research because of their importance in studying gland development, hormonal regulation, lactation physiology, and neoplastic transformation (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). These cultures serve as essential reference models for investigating basic physiological processes such as proliferation, hormonal interactions and differentiation. In the context of cancer research, they allow for direct comparison with tumor cells, assisting to identify cancer specific alterations. Additionally, they are invaluable for assessing treatment methods and play a key role in the development and validation of diagnostic and prognostic markers for canine mammary tumors (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref9">9</xref>).</p>
<p>In line with this, the present study aimed to establish and characterize primary epithelial cell cultures from healthy canine mammary gland (CMG) tissue as a relevant <italic>in vitro</italic> model for studying normal mammary biology and early neoplastic transformation. Key objectives included: confirming the physiological status of donor tissue via histology; assessing cell morphology, adherence, and proliferation using xCELLigence and XTT assays; and verifying epithelial identity through immunofluorescence staining (pan-CK, CK8/18, MUC1, Ki-67). By optimizing growth conditions and validating cell phenotypes, the study provides a foundation for developing standardized cell lines to support comparative oncology and personalized veterinary therapies.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Animals and tissue samples</title>
<p>At the beginning of the experiment, informed consent was obtained from the owners of the animals to collect biological material. The research protocols were approved by the ethics committee of the UVMP in Ko&#x0161;ice (EKVP/2023&#x2013;02). The tissue donors were two female dogs, an 8-year-old French Bulldog (C1) with a weight of approximately 9&#x202F;kg and a 1-year-old Dachshund (C2) with a weight of 7.7&#x202F;kg. The collection of healthy mammary gland tissue (n&#x202F;=&#x202F;2) was performed during preventive ovariohysterectomy at Small Animal Clinic UVMP in Ko&#x0161;ice according to the standard veterinary procedures under strict sterile conditions. After surgical excision, the tissue sample (approx. 1&#x202F;cm<sup>3</sup>) was transported to the laboratory in a sterile solution consisting of 1x phosphate-buffered saline (PBS, Sigma, United States) supplemented with 0.02% gentamicin solution (50&#x202F;mg/mL, Sigma, USA). The tissue was mechanically divided into smaller pieces under sterile conditions. A portion of the tissue was transferred into PBS containing gentamicin (0.02%) for subsequent cell isolation. Smaller fragments of glandular tissue (approx. 0.5&#x202F;cm<sup>3</sup>) were immediately fixed in 4% formaldehyde to preserve the tissue architecture for histological and immunohistochemical analysis.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Isolation of primary cell cultures</title>
<p>The isolation of primary cell cultures was performed in a Biosafety Cabinets (Herasafe, Class II Biological Safety Cabinet, Thermo Fisher Scientific Inc., United States, BioSafe, Class II. A2, Ekokrok, SK) under sterile conditions to prevent contamination by unwanted pathogens. The canine mammary gland tissue immersed in PBS was first mechanically dissociated using surgical instruments. Then enzymatic digestion was performed with 1&#x202F;mg/mL collagenase IV (Gibco, Invitrogen, Carlsbad, CA, United States) in Earle&#x2019;s Balanced Salts Solution (Biosera, France) supplemented by 1% Antibiotic/Antimycotic solution (ATB/ATM, 1% solution of penicillin (10,000&#x202F;U/mL), streptomycin (10,000&#x202F;&#x03BC;g/mL), and amphotericin B (25&#x202F;&#x03BC;g/mL)Sigma, United States) and 0.1% gentamicin. After 45&#x202F;min of incubation at 37&#x202F;&#x00B0;C, the enzyme was neutralized with the same volume of fetal bovine serum (FBS, Sigma, United States). The digested tissue was filtered through a cell strainer with the size of 100&#x202F;&#x03BC;L and centrifuged at 1200&#x202F;rpm/ 7&#x202F;min. The cell pellet was resuspended in 1&#x202F;mL of culture medium Dulbecco&#x2019;s modified Eagle&#x2019;s medium High Glucose (DMEM HG, Sigma, CA, United States). The cells were plated on a 25&#x202F;cm<sup>2</sup> tissue culture flask/T25 (Corning, Lowell, MA, United States) and maintained in a humidified atmosphere containing 5% CO<sub>2</sub> at 37&#x202F;&#x00B0;C.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Morphology, cultivation, and cryopreservation of primary cell cultures</title>
<p>CMG cells were cultivated in DMEM HG supplemented with 10% FBS, 2% ATB/ATM solution, 0.1% gentamicin, and 1% L-glutamine (Sigma, United States) under standard culture conditions (5% CO<sub>2</sub> at 37&#x202F;&#x00B0;C) until the formation of a monolayer. The medium was changed every 2&#x2013;3&#x202F;days of incubation. The adherence properties, morphology and expansion capacity of CMG cells were evaluated after 24, 48, and 72&#x202F;h of cultivation using the inverted microscope Zeiss Axiovert 200 equipped with a digital acquisition system. When the cell confluence reached 80&#x2013;90%, primary culture cells were subcultured to establish passage 1 (P1). The CMG cells were washed with PBS and detached from the bottom of the culture flask using 1&#x202F;mL of 0.05% trypsin/EDTA solution (Sigma, CA, United States). After incubation for 3&#x2013;5&#x202F;min at 37&#x202F;&#x00B0;C, the enzyme was deactivated with the same volume of FBS. The suspension of cells was centrifuged at 1200&#x202F;rpm/ 7&#x202F;min. The supernatant was removed, and 1&#x202F;mL of DMEM HG was added for resuspension of the cell pellet. Afterward, the cells were counted in a trypan blue 4% solution using a hemocytometer under an inverted microscope. For the counting of the total number of cells, the calculation formula was used: Total number of cells/ml&#x202F;=&#x202F;(Number of viable cells &#x00D7; dilution factor&#x00D7;10<sup>4</sup>)/(Number of squares counted). The percentage of viable cells was calculated as (the number of viable cells / total number of cells)&#x202F;&#x00D7;&#x202F;100. The part of the pellet was plated on a 75&#x202F;cm<sup>2</sup> tissue culture flask/T75&#x202F;cm<sup>2</sup> (Corning, Lowell, MA, United States) for further experiments. The rest of the cell pellet was centrifuged (1,200&#x202F;rpm/7&#x202F;min) and resuspended in freezing medium composed of 50% DMEM HG, 40% FBS and 10% dimethyl sulfoxide (DMSO, Sigma, United States). The cells in cryogenic vials (Ratiolab, Deutschland) were frozen at 1&#x202F;&#x00B0;C/min in MrFrosty Freezing Container (Sigma, USA) in 80&#x202F;&#x00B0;C for 24&#x202F;h and subsequently stored in liquid nitrogen.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Growth assay</title>
<p>The growth curve of cultured cells was evaluated using the xCELLigence system, Real-Time Cell Analyzer (RTCA, Roche Applied Sciences, Mannheim, Germany) and XTT assay.</p>
<p>The RTCA is a system that relies on electronic detection to monitor biological processes. The RTCA uses E-plates (Acea Bioscience, San Diego, CA, United States) equipped with gold microelectrodes on the surface of the culture plate. These electrodes measure electrical impedance, which allows the system to detect changes in cell properties, such as their adherence, changes in morphology, or proliferation (<xref ref-type="bibr" rid="ref10">10</xref>). All the changes are expressed as cell index (CI) and recorded in curves. The CMG cells at passage 1 (P1) were seeded into 96-well E-plates at different concentrations of cells, 1 &#x00D7; 10<sup>3</sup>, 2 &#x00D7; 10<sup>3</sup>, 4 &#x00D7; 10<sup>3</sup>, and 8 &#x00D7; 10<sup>3</sup> cells per well in 200&#x202F;&#x03BC;L of DMEM HG supplemented with 2% ATB/ATM solution, in triplicate, and cultured at 37&#x202F;&#x00B0;C and 5% CO<sub>2</sub> for a total of 100&#x202F;h. The results were experimentally evaluated following the manufacturer&#x2019;s instructions for the xCELLigence Real-Time Cell Analyzer (RTCA, ACEA Biosciences, United States).</p>
<p>XTT assay is used for the detection of viable, metabolically active cells, which can reduce yellow XTT dye into orange formazan. The cells (P1) were seeded in a 96-well plate at the same concentrations as those used for the xCELLigence assay, in 100&#x202F;&#x03BC;L of DMEM HG. After three incubation times (24, 48, and 72&#x202F;h), 50&#x202F;&#x03BC;L of freshly prepared XTT solution, composed of XTT labeling reagent and electron coupling reagent in a ratio 50:1, was added to the wells. The plates were incubated at 37&#x202F;&#x00B0;C and 5% CO<sub>2</sub> for 4&#x202F;h. The absorbance was measured at a wavelength of 450&#x202F;nm using the APOLLO Absorbance Reader (Berthold Systems, United States) to analyze cell viability.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>Sample preparation for light microscopy evaluation</title>
<p>The tissue samples were immersed in 4% formaldehyde, then dehydrated through a graded series of ethanol (50, 70, 100%), transferred to xylene, and embedded in Paraplast blocks (Sigma-Aldrich). Serial sections (<italic>n</italic>&#x202F;=&#x202F;6), 6&#x202F;&#x03BC;m thick obtained from each block were stripped of paraplast and stained using a routine hematoxylin and eosin (H&#x0026;E) method. Sections were evaluated using a Zeiss Axio Lab A1 light microscope and photodocumented using an Axio Cam ERc 5 camera. Twenty (<xref ref-type="bibr" rid="ref11">11</xref>) randomly selected fields of each tissue section were evaluated by two independent histologists.</p>
</sec>
<sec id="sec8">
<label>2.6</label>
<title>Immunocytochemistry</title>
<p>CMG cells (P2) were seeded on round coverslips (diameter&#x202F;=&#x202F;12&#x202F;mm) placed in 24-well plates (1.5 &#x00D7; 10<sup>4</sup> cells / well) in a final volume of 500&#x202F;&#x03BC;L. After reaching confluency (4&#x202F;days), cells were washed with PBS and fixed with 4% paraformaldehyde (pH&#x202F;=&#x202F;7.2) for 20&#x202F;min at room temperature. Following fixation, CMG cells were washed again with PBS and incubated in a solution of 10% normal goat serum (NGS) in PBS supplemented with 0.2% Triton X-100 (PBS TX100) for 1&#x202F;h at room temperature. This process ensures better access of the antibody to intracellular proteins and minimizes non-specific binding. Primary antibodies (<xref ref-type="table" rid="tab1">Table 1</xref>) diluted in PBS TX100 were added to the cells for 24&#x202F;h at 4&#x202F;&#x00B0;C. The following day, CMG cells were washed with PBS and incubated with the appropriate secondary antibodies (<xref ref-type="table" rid="tab1">Table 1</xref>) diluted in PBS TX100 for 1&#x202F;h at room temperature in the dark. During this step, DAPI (1:200) was also added to the cells to stain nuclei. Lastly, cells were washed with PBS three times for 5&#x202F;min. Coverslips were mounted to the slides using Vectashield mounting medium (Cole-Parmer, Vernon Hills, IL, United States) and analyzed by a Zeiss AxioVision-APOTOM fluorescence microscope. Negative controls were prepared by excluding the primary antibodies from the staining procedure.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>List of antibodies used for immunofluorescence staining of cells and tissues.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" colspan="4">Primary antibodies</th>
</tr>
<tr>
<th align="left" valign="top">Name</th>
<th align="center" valign="top">Catalog number</th>
<th align="center" valign="top">Dilution</th>
<th align="left" valign="top">Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Ki-67, RBX-500 UL</td>
<td align="center" valign="top">ab15580</td>
<td align="center" valign="top">1:300</td>
<td align="left" valign="top">Abcam</td>
</tr>
<tr>
<td align="left" valign="top">Mouse Cytokeratin, pan mAb (AE-1/AE-3)</td>
<td align="center" valign="top">NBP2-29429</td>
<td align="center" valign="top">1:100</td>
<td align="left" valign="middle" rowspan="3">Biotechne</td>
</tr>
<tr>
<td align="left" valign="top">Mouse mAb anti-Cytokeratin 8/18 (5D 3)</td>
<td align="center" valign="top">NB120-17139</td>
<td align="center" valign="top">1:100</td>
</tr>
<tr>
<td align="left" valign="top">Mouse anti-MUC1 (OTI2E3)</td>
<td align="center" valign="top">NBP2-45838</td>
<td align="center" valign="top">1:200</td>
</tr>
<tr>
<td align="left" valign="top">Flex Polyclonal Rabbit Anti-S100</td>
<td align="center" valign="top">IR504</td>
<td align="center" valign="top">1:200</td>
<td align="left" valign="middle">Dako</td>
</tr>
<tr>
<td align="left" valign="top">Vimentin Monoclonal Antibody (V9)</td>
<td align="center" valign="top">MA5-11883</td>
<td align="center" valign="top">1:250</td>
<td align="left" valign="middle">Invitrogen</td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" colspan="4">Secondary antibodies</th>
</tr>
<tr>
<th align="left" valign="top">Name</th>
<th align="center" valign="top">Catalog number</th>
<th align="center" valign="top">Dilution</th>
<th align="left" valign="top">Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Alexa Fluor&#x2122; 488 Goat anti-Rabbit IgG (H&#x202F;+&#x202F;L)</td>
<td align="center" valign="top">A-11034</td>
<td align="center" valign="top">1:200</td>
<td align="left" valign="middle" rowspan="4">Invitrogen</td>
</tr>
<tr>
<td align="left" valign="top">Alexa Fluor&#x2122; 488 Goat anti-Mouse IgG (H&#x202F;+&#x202F;L)</td>
<td align="center" valign="top">A-11001</td>
<td align="center" valign="top">1:200</td>
</tr>
<tr>
<td align="left" valign="top">Alexa Fluor&#x2122; 594 Goat anti-Mouse IgG (H&#x202F;+&#x202F;L)</td>
<td align="center" valign="top">A-11032</td>
<td align="center" valign="top">1:200</td>
</tr>
<tr>
<td align="left" valign="top">Alexa Fluor&#x2122; 594 Goat anti-Rabbit IgG (H&#x202F;+&#x202F;L)</td>
<td align="center" valign="top">A-11037</td>
<td align="center" valign="top">1:200</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec9">
<label>2.7</label>
<title>Immunohistochemistry</title>
<p>For immunohistochemistry, samples were prepared similarly to the (H&#x0026;E) staining. The sections were stripped of paraplast and antigen retrieval was carried out with 10&#x202F;mM citrate buffer (pH&#x202F;=&#x202F;6) for 10&#x202F;min at 97&#x202F;&#x00B0;C, followed by washing with PBS. Then, incubation with 10% NGS, primary and secondary antibodies (<xref ref-type="table" rid="tab1">Table 1</xref>) was performed by the same methodological procedure as for immunocytochemical staining described above. Vectashield medium was used to mount coverslips to the slides. The stained sections were evaluated using a Zeiss AxioVision-APOTOM fluorescence microscope.</p>
</sec>
</sec>
<sec sec-type="results" id="sec10">
<label>3</label>
<title>Results</title>
<sec id="sec11">
<label>3.1</label>
<title>General features of primary canine mammary gland cells</title>
<p>With the protocol established herein, primary cells from canine mammary gland tissue were isolated by enzymatic digestion and plated in a culture flask (T25) under standard conditions. The yield of isolated cells was approximately 1 &#x00D7; 10<sup>6</sup> cells/mL. By the following day, part of the cells had already adhered and changed their shape to a polygonal one. Some rounded precursor cells with light cytoplasm were still actively divided (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). At 48&#x202F;h post-plating, the first medium change was performed, and the cells showed a good attachment to the surface, displaying polygonal and fibroblast-like shapes (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The non-attached material, composed of degenerated cells and detritus, was washed away. After 6&#x2013;7&#x202F;days, the monolayers were confluent (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), and the CMG cells were subcultured without losing their proliferative properties. Cell viability before each experiment was greater than 95%.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Morphological development of primary CMG cells. Phase-contrast images show CMG cells at passage 0 (P0) on day <italic>in vitro</italic> (DIV) 1 <bold>(A)</bold>, DIV 2 <bold>(B)</bold>, and DIV 7 <bold>(C)</bold>. Cells exhibited initial adherence and polygonal morphology by DIV 1, progressing to fibroblast-like shape (DIV 2) with increased confluence and organization into a monolayer by DIV 7. Scale bars: 50&#x202F;&#x03BC;m.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Three-panel image showing different stages of cell culture. Panel A displays sparse, individual cells scattered randomly. Panel B shows a colony of cells beginning to cluster. Panel C illustrates densely packed, elongated cells with a uniform alignment, indicating a high level of confluence. Each panel is labeled A, B, and C, respectively.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec12">
<label>3.2</label>
<title>Histological evaluation of canine mammary gland tissue</title>
<p>The mammary gland of the female dog (C1) (French Bulldog breed) during active lactation consisted of large lobules separated by connective tissue septa. Each lobule contained very well-developed secretory units, alveoli and tubules, which were surrounded by a sparse loose connective tissue-interstitium with small blood vessels. Alveoli, ranging from spherical to ovoid shape and elongated tubules were lined with tall, simple cuboidal secretory epithelium. Lactiferous content was observed in the lumens of both tubules and alveoli. Within the lobules, small intralobular ducts lined by low, simple cuboidal epithelium were found. Septa separating individual lobules contained very well-developed interlobular ducts with large, irregular lumens filled with secretory product/milk (<xref ref-type="fig" rid="fig2">Figures 2A</xref>,<xref ref-type="fig" rid="fig2">B</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Histological structure of the healthy canine mammary gland during active lactation <bold>(A,B)</bold> and regression <bold>(C,D)</bold>. Panels <bold>A</bold> and <bold>B</bold> show well-developed alveoli (al) and tubules (tu) organized within lobules separated by connective tissue septa (se). Alveoli, tubules, and ducts (du) contained secretory product - milk (&#x002A;). Panels <bold>C</bold> and <bold>D</bold> illustrate regressive changes of the glandular tissue manifested by collapsed alveoli (al&#x2032;), distended interlobular ducts (du&#x2032;) with only occasional occurrence of secretion/milk (&#x002A;), and expanded connective tissue septa (se&#x00B4;) and interstitium (in&#x00B4;). Scale bar: 100&#x202F;&#x03BC;m, H&#x0026;E staining.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Histological slides show tissue sections labeled A to D. Each image displays various structures with annotations: "tu" for tubules, "in" for interstitial tissue, "se" for seminiferous epithelium, "al" for albuginea, "du" for duct, and asterisks marking specific areas of interest. The scale bar indicates 100 micrometers.</alt-text>
</graphic>
</fig>
<p>In the second dog (C2) (Dachshund), the mammary gland was in regression state, and its secretory alveoli and tubules were irregularly shaped, shrunken, and often with completely collapsed lumens. Some alveoli still contained secretory product/milk. The interlobular ducts were highly distended and lined with low, simple cuboidal epithelium. Secretory product was not always found in their lumens. The connective tissue stroma was enlarged (<xref ref-type="fig" rid="fig2">Figures 2C</xref>,<xref ref-type="fig" rid="fig2">D</xref>).</p>
</sec>
<sec id="sec13">
<label>3.3</label>
<title>Growth curve</title>
<sec id="sec14">
<label>3.3.1</label>
<title>Proliferation dynamics assessed by real-time monitoring (xCELLigence system)</title>
<p>The proliferation behavior of primary CMG cells (P1) was evaluated in real time using the xCELLigence system (RTCA), which quantifies the CI as a composite measure of cell number, size, and adhesion. Both CMG cell populations&#x2014;C1 and C2&#x2014;demonstrated rapid growth at initial seeding densities of 4,000 and 8,000 cells/well (<xref ref-type="fig" rid="fig3">Figures 3A</xref>,<xref ref-type="fig" rid="fig3">B</xref>). For C2, increased proliferation was also observed at 2,000 cells/well, though to a lesser extent.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Real-time monitoring of CMG cell proliferation using the xCELLigence system. Growth curves of CMG cell populations C1 <bold>(A)</bold> and C2 <bold>(B)</bold> seeded at 1,000&#x2013;8,000 cells/well.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Line graphs labeled A and B display cell index against time over ninety-six hours for different cell concentrations. Graph A shows a peak at twenty-four hours for 1000 and 8000 cells, with declines afterward. Graph B indicates similar initial peaks for 8000 and 4000 cells, remaining stable or declining. Both graphs compare different cell concentrations and DMEM HG medium, indicating varied cell growth patterns over time. Vertical orange lines mark twenty-four, forty-eight, and seventy-two hours.</alt-text>
</graphic>
</fig>
<p>After 48&#x202F;h, cells at higher densities began to plateau, indicating the onset of contact inhibition. Cultures seeded at 8,000 cells/well reached 80&#x2013;90% confluence by this time point, after which the CI values slightly declined&#x2014;suggesting spatial limitations and reduced proliferative activity. In contrast, cells seeded at 4,000 cells/well maintained steady growth between 24 and 72&#x202F;h, indicating this density as optimal for further <italic>in vitro</italic> experimentation.</p>
</sec>
<sec id="sec15">
<label>3.3.2</label>
<title>Metabolic activity assessment by XTT assay</title>
<p>To complement real-time proliferation data, metabolic activity of CMG cells (P1) was measured using the XTT assay under identical seeding conditions. As shown in <xref ref-type="fig" rid="fig4">Figures 4A</xref>,<xref ref-type="fig" rid="fig4">B</xref>, cells seeded at 8,000 cells/well exhibited high metabolic activity within the first 48&#x202F;h, correlating with the observed early confluence. However, this activity declined thereafter.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Metabolic activity of CMG cells assessed by XTT assay. CMG cell populations C1 <bold>(A)</bold> and C2 <bold>(B)</bold> were plated at 1000&#x2013;8000 cells/well under identical conditions to the xCELLigence assay.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Growth curve graphs show absorbance at 450 nanometers over 72 hours of incubation. Graph A peaks at 1.6 absorbance, and Graph B peaks at 3.6 absorbance. Data points for concentrations are 8000, 4000, 2000, and 1000; represented by circles, squares, triangles, and inverted triangles, respectively.</alt-text>
</graphic>
</fig>
<p>Notably, the highest and most sustained metabolic activity over time was recorded in cultures seeded at 4,000 cells/well, corroborating the xCELLigence findings. This concentration supported both robust proliferation and sustained viability, thereby confirming it as the optimal initial seeding density for primary CMG cell culture.</p>
</sec>
</sec>
<sec id="sec16">
<label>3.4</label>
<title>Immunofluorescence analysis of canine mammary gland cells</title>
<p>Immunofluorescence staining was performed to assess the expression of epithelial, mesenchymal and proliferation markers in primary CMG cells (P2) and corresponding tissue samples. The evaluated markers included pan-cytokeratin (pan-CK), cytokeratin 8/18 (CK8/18), mucin-1 (MUC1), Ki-67, vimentin and S100. Strong cytoplasmic positivity for pan-CK and CK8/18 was observed in cultured CMG cells, confirming their epithelial origin (<xref ref-type="fig" rid="fig5">Figures 5</xref>, <xref ref-type="fig" rid="fig6">6</xref>). These cytokeratins, which are structural components of the intermediate filament cytoskeleton, are widely used to identify luminal epithelial cells in both normal and neoplastic mammary tissue. Expression patterns in cultured cells closely resembled those observed in native mammary gland tissue.</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Immunofluorescence staining of pan-cytokeratin (pan-CK) in primary CMG cells and tissue. Pan-CK (green) expression confirmed the epithelial identity of CMG cells in culture <bold>(A,B,D,E)</bold> and tissue sections <bold>(C,F)</bold>. Nuclei are stained with DAPI (blue). <bold>B</bold> and <bold>E</bold> show magnified regions of <bold>A</bold> and <bold>D</bold>, respectively. Magnification: A, C, D, <italic>F</italic>&#x202F;=&#x202F;100x; B, E&#x202F;=&#x202F;400x.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g005.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Fluorescent microscopy images showing Pan-CK staining in green and cell nuclei in blue. Panels A to C1 depict tissue samples from one case, while panels D to F from another. Each panel highlights cellular structures and protein presence, with dashed boxes indicating magnified areas in B and E.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>Immunofluorescence staining of cytokeratin 8/18 (CK8/18) in primary CMG cells and tissue. CK8/18 expression was observed in the cytoplasm of CMG cells <bold>(A,B,D,E)</bold> and corresponding mammary tissue <bold>(C,F)</bold>, confirming luminal epithelial identity. Signals were visualized in red or green, depending on antibody labeling. Nuclei were counterstained with DAPI (blue). Panels <bold>B</bold> and <bold>E</bold> show magnified views of <bold>A</bold> and <bold>D</bold>, respectively. Magnification: A, C, D, F&#x202F;=&#x202F;100x; B, E&#x202F;=&#x202F;400x.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g006.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Panel of six fluorescent microscopy images labeled A to F under "CK 8/18". Panels A to C1 show red fluorescent staining with a blue background, highlighting cellular features. Panel C displays tissue structure with detailed contours. Panels D to F in C2 show green fluorescence with blue, highlighting elongated cell shapes and tissue structure, with some visible nuclei. Each row presents different staining patterns or magnifications.</alt-text>
</graphic>
</fig>
<p>MUC1, a transmembrane glycoprotein involved in epithelial cell protection and adhesion, was abundantly expressed in CMG cells, with apical localization consistent with non-malignant epithelial differentiation (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>Immunofluorescence staining of MUC1 in primary canine mammary gland (CMG) cells and tissue. Representative images show strong MUC1 expression (green) with apical localization in cultured CMG cells <bold>(A,B,D,E)</bold> and corresponding tissue samples <bold>(C,F)</bold>. Nuclei are counterstained with DAPI (blue). Panels <bold>B</bold> and <bold>E</bold> represent details of <bold>A</bold> and <bold>D</bold>, respectively. Magnification: A, C, D, F&#x202F;=&#x202F;100x; B, E&#x202F;=&#x202F;400x.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g007.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Fluorescent microscopy images showing cellular expression of MUC1. Panels A, B, and C (C1 label) display scattered cells with green fluorescence, indicating MUC1 presence, and blue nuclear staining. Panels D, E, and F (C2 label) show elongated, dense patterns with a similar staining setup. Panel B and E are magnified views showing detailed cellular structure. Panel C and F depict tissue-like structures.</alt-text>
</graphic>
</fig>
<p>Analysis of the nuclear proliferation marker Ki-67 revealed low expression levels, indicating a moderate proliferative state in cultured CMG cells (<xref ref-type="fig" rid="fig8">Figure 8</xref>). This was consistent with their non-transformed phenotype and supports their relevance as a model for physiologically normal mammary epithelium.</p>
<fig position="float" id="fig8">
<label>Figure 8</label>
<caption>
<p>Immunofluorescence staining of the proliferation marker Ki-67 in primary CMG cells and tissue. Low levels of nuclear Ki-67 expression (red) were detected in cultured cells <bold>(A,B,D,E)</bold> and tissue samples <bold>(C,F)</bold>, indicating a moderate proliferative state. Nuclei were stained with DAPI (blue). Panels <bold>B</bold> and <bold>E</bold> show magnified regions of <bold>A</bold> and <bold>D</bold>, respectively. Magnification: A, C, D, F&#x202F;=&#x202F;100x; B, E&#x202F;=&#x202F;400x.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g008.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Fluorescent microscopy images showcasing cell staining with Ki67 antibody. Panels A and B display green and blue-stained cells, respectively, highlighting nuclear and cellular features. Panel C shows a detailed network structure. Panels D and E feature red and blue-stained cells, indicating nuclear activity. Panel F shows complex tissue architecture with red highlighting specific structures.</alt-text>
</graphic>
</fig>
<p>Vimentin is an intermediate filament protein predominantly expressed in mesenchymal cell types. Fibroblasts generally display vimentin intermediate filaments (VIFs) evenly dispersed throughout their cytoplasm (<xref ref-type="bibr" rid="ref12">12</xref>).</p>
<p>The S100 family comprises calcium-binding proteins involved in cell homeostasis, growth, proliferation, and differentiation, and is associated with cancer progression. S100 proteins are expressed in several cell types including fibroblasts, nerve cells and mammary myoepithelial cells (<xref ref-type="bibr" rid="ref13 ref14 ref15 ref16 ref17">13&#x2013;17</xref>). Negative expression of both mesenchymal markers, vimentin and S100, was observed in CMG cells (<xref ref-type="fig" rid="fig9">Figures 9</xref>, <xref ref-type="fig" rid="fig10">10</xref>). Negative controls showed no specific staining for any of the investigated markers (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figures S1&#x2013;S3</xref>).</p>
<fig position="float" id="fig9">
<label>Figure 9</label>
<caption>
<p>Immunofluorescence analysis of mesenchymal marker vimentin in primary CMG cells. Negative expression was observed in CMG cells <bold>(A&#x2013;D)</bold> indicating non-mesenchymal potential of cells. Nuclei were stained with DAPI (blue). Panels <bold>B</bold> and <bold>D</bold> are details of <bold>A</bold> and <bold>B</bold>. Magnification: <bold>(A)</bold>, C&#x202F;=&#x202F;100&#x00D7;; <bold>(B)</bold>, D&#x202F;=&#x202F;400&#x202F;&#x00D7;.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g009.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Fluorescence microscopy images showing vimentin expression in cells. Panels A and C display clustered cell formations with blue nuclei and green cytoplasmic staining, highlighting vimentin. Panels B and D are magnified views of the highlighted regions in A and C, showing individual blue nuclei with minimal green signaling.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig10">
<label>Figure 10</label>
<caption>
<p>Immunofluorescence staining of protein S100 in primary canine mammary cells. Expression of marker S100 was negative in CMG cells <bold>(A&#x2013;D)</bold>, indicating epithelial luminal origin of cells. Nuclei were counterstained with DAPI (blue). Panels <bold>B</bold> and <bold>D</bold> show magnified views of <bold>A</bold> and <bold>C</bold>, respectively. Magnification: <bold>(A)</bold>, C&#x202F;=&#x202F;100&#x00D7;; <bold>(B)</bold>, E&#x202F;=&#x202F;400&#x202F;&#x00D7;.</p>
</caption>
<graphic xlink:href="fvets-12-1652991-g010.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Two pairs of fluorescent microscopy images labeled C1 and C2, each with panels A and B, C and D. Panels A and C show numerous blue-stained cells with highlighted regions, while panels B and D present magnified views of cells with blue nuclei. Background appears green.</alt-text>
</graphic>
</fig>
<p>The immunofluorescence panel applied in this study (pan-CK, CK8/18, MUC1, Ki-67, vimentin and S100) consistently showed a luminal epithelial phenotype in cultured CMG cells. We did not detect a distinct cell population with morphological or immunophenotypic features compatible with myoepithelial cells, indicating that the established cultures are luminal-enriched epithelial monolayers.</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec17">
<label>4</label>
<title>Discussion</title>
<p>The mammary gland, a modified sweat gland, exhibits significant development in females and remains rudimentary in males (<xref ref-type="bibr" rid="ref18">18</xref>). It is among the few mammalian tissues capable of undergoing cyclical morphological and functional changes - growth, differentiation, and regression - throughout the female&#x2019;s reproductive life, particularly during puberty, pregnancy, lactation, and involution (<xref ref-type="bibr" rid="ref19">19</xref>). This high degree of hormonal responsiveness renders mammary tissue particularly susceptible to neoplastic transformation (<xref ref-type="bibr" rid="ref9">9</xref>, <xref ref-type="bibr" rid="ref20">20</xref>).</p>
<p>Mammary gland development initiates during embryogenesis with the formation of a rudimentary ductal tree embedded in the mammary fat pad (<xref ref-type="bibr" rid="ref19">19</xref>). At the onset of puberty, ovarian hormones drive further ductal and alveolar development: estrogen promotes ductal elongation, while progesterone and prolactin orchestrate alveolar morphogenesis (<xref ref-type="bibr" rid="ref11">11</xref>, <xref ref-type="bibr" rid="ref21">21</xref>). During pregnancy, adipose tissue is replaced by glandular epithelium capable of milk secretion. Following weaning, the gland undergoes involution, characterized by apoptosis and extracellular matrix remodeling (<xref ref-type="bibr" rid="ref22">22</xref>).</p>
<p>Histologically, the active mammary gland comprises secretory alveoli and secretory tubules lined by cuboidal epithelium, supported by myoepithelial cells and a richly vascularized stroma. In contrast, the inactive gland post-lactation exhibits atrophy, with reduced parenchyma replaced by adipose tissue (<xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). These phases were evident in our histological analysis (H&#x0026;E): lactating tissue displayed well-developed alveolar structures, whereas tissue in regression showed disorganized, collapsed alveoli and expanded stromal components, aligning with previously published descriptions of the dynamic remodeling capacity of mammary tissue.</p>
<p>Canine mammary tumors (CMTs) are among the most common neoplasms in intact female dogs, accounting for a significant proportion of tumors in this population, with approximately half exhibiting malignant potential and metastatic behavior (<xref ref-type="bibr" rid="ref25">25</xref>). Due to significant histopathological, hormonal, and molecular similarities with human BC, including shared oncogenic pathways and hormone responsiveness, CMTs serve as a valuable spontaneous model for translational BC research (<xref ref-type="bibr" rid="ref26">26</xref>).</p>
<p>Historically, immortalized cell lines have been central to <italic>in vitro</italic> studies on CMTs. While these models offer consistency and scalability, they often fail to replicate the dynamic cellular heterogeneity and microenvironmental interactions of native tissues (<xref ref-type="bibr" rid="ref27">27</xref>). Additionally, long-term culturing can induce genetic drift, reducing their translational fidelity and clinical relevance (<xref ref-type="bibr" rid="ref28">28</xref>). These limitations have prompted a shift toward primary cell cultures derived directly from fresh tissue biopsies, which better retain <italic>in vivo</italic> phenotypic characteristics and patient-specific responses.</p>
<p>In our study, we successfully established a two-dimensional primary culture model from healthy CMG tissue using a combined mechanical and enzymatic dissociation protocol. This approach enabled efficient cell isolation, with cells demonstrating robust adherence, rapid proliferation, and confluence within 7&#x202F;days (<xref ref-type="bibr" rid="ref29">29</xref>). This methodological choice aligns with protocols employed in previous studies that utilized combined mechanical and enzymatic dissociation techniques to optimize cell yield and viability in canine mammary tissue (<xref ref-type="bibr" rid="ref30 ref31 ref32">30&#x2013;32</xref>). In contrast (<xref ref-type="bibr" rid="ref33">33</xref>), reported the successful isolation of primary CMT cells using a mechanical-only method, although this approach may be less efficient for tissues with intact extracellular matrix or limited enzymatic susceptibility.</p>
<p>The efficacy of our combined dissociation method is further supported by the findings of Petrou&#x0161;kov&#x00E1; et al. (<xref ref-type="bibr" rid="ref31">31</xref>), who established primary cell cultures from CMG tumors using mechanical disaggregation and enzymatic digestion with type IV collagenase. Their cultures achieved confluency by day 7 and exhibited high expression of epithelial markers along with significant proliferation activity. These results corroborate our observations of rapid cell proliferation and marker expression in primary CMG cultures. Regardless of the technique, published studies consistently report that isolated primary mammary cells - whether from tumor or normal tissue - retain the capacity for proliferation and <italic>in vitro</italic> propagation. Our findings corroborate this, as the CMG cells maintained their proliferative potential across passages, suggesting that our dissociation method preserved cellular integrity and stemness features relevant for subsequent experimentation.</p>
<p>Histological analysis of donor tissue revealed a well-organized lobular structure with active alveoli and ducts, lined by tall cuboidal epithelium and containing lactiferous secretions - features typical of lactating canine mammary glands (<xref ref-type="bibr" rid="ref34">34</xref>). Similar architecture and epithelial marker expression were reported in tumor-derived cultures (<xref ref-type="bibr" rid="ref31">31</xref>), supporting the tissue&#x2019;s physiological integrity. By establishing a primary culture from non-neoplastic CMG tissue, we provide a relevant model for studying normal epithelial biology and early neoplastic changes. This model also offers a benchmark for assessing drug specificity and cytotoxicity, contributing to more accurate preclinical testing and personalized therapy development.</p>
<p>The establishment of primary cell cultures from healthy CMG tissue provides a physiologically relevant model for studying normal mammary function and early neoplastic transformation. To assess proliferative behavior and metabolic activity, we employed the xCELLigence system RTCA and the XTT assay, aiming to define optimal seeding densities for <italic>in vitro</italic> applications. RTCA, which continuously monitors cell proliferation, adhesion, and morphology through electrical impedance, revealed that primary CMG cells seeded at both 4,000 and 8,000 cells/well exhibited rapid early growth, with a clear plateau phase observed after 48&#x202F;h. However, while 8,000 cells/well resulted in a sharp initial increase in CI due to rapid proliferation and early confluence (80&#x2013;90%), this was followed by a decline in growth rate, likely driven by spatial constraints and contact inhibition. In contrast, cultures seeded at 4,000 cells/well displayed sustained and linear proliferation over a 24&#x2013;72&#x202F;h period, identifying this density as optimal for subsequent <italic>in vitro</italic> experimentation. These findings were corroborated by the XTT assay, which evaluates mitochondrial metabolic activity. CMG cells seeded at 8,000 cells/well showed high metabolic activity only during the first 48&#x202F;h, after which activity declined, consistent with the plateau and growth inhibition observed in the xCELLigence data. Conversely, cells seeded at 4,000 cells/well maintained higher metabolic activity over a longer duration, supporting their continued viability and proliferative capacity. Together, these data point out the critical importance of optimizing initial seeding density in primary cell cultures to ensure that cells remain in the exponential growth phase. Such standardization enhances reproducibility and reliability in downstream biological and pharmacological assays, particularly in models intended for translational veterinary and comparative oncology research. Our findings align with previous studies using xCELLigence to track proliferation dynamics, such as de Oliveira et al. (<xref ref-type="bibr" rid="ref51">51</xref>), who used the system to assess glycolysis inhibition in colorectal cancer cells. Likewise, the XTT assay remains a standard for evaluating mitochondrial activity and viability across diverse cell types. Importantly, this study is the first to define optimal seeding density for primary cultures derived from healthy mammary tissue in a 24-well format. In contrast, Petrou&#x0161;kov&#x00E1; et al. (<xref ref-type="bibr" rid="ref33">33</xref>) used a lower density (1,000 cells/well) for CMT cultures, reflecting the higher proliferative capacity and altered phenotype of neoplastic cells, which also showed elevated expression of MUC1, CK8/18, and Ki-67. Optimizing growth conditions for healthy CMG cells offers a critical baseline for exploring mammary gland biology, hormonal regulation, and early tumorigenesis. This model also supports the assessment of drug effects on non-malignant cells, key for enhancing therapeutic specificity and safety (<xref ref-type="bibr" rid="ref35">35</xref>). Ultimately, such cultures contribute to the goals of personalized medicine by replicating normal tissue physiology and advancing both basic and translational veterinary oncology research.</p>
<p>Our immunofluorescence analysis of primary CMG cells revealed robust expression of pan-CK and CK8/18, affirming their epithelial identity (<xref ref-type="bibr" rid="ref36">36</xref>). Pan-CK antibodies, such as AE1/AE3, target a broad spectrum of cytokeratins, making them effective markers for epithelial cells in both canine and human tissues (<xref ref-type="bibr" rid="ref37">37</xref>). CK8 and CK18 are intermediate filament proteins characteristic of luminal mammary epithelial cells, and their strong expression in CMG cultures mirrors their localization in normal human breast tissue, indicating a well-differentiated epithelial phenotype (<xref ref-type="bibr" rid="ref38">38</xref>, <xref ref-type="bibr" rid="ref39">39</xref>). In human BC, the expression patterns of CK8/18 are associated with tumor subtypes and prognoses. Retention of CK8/18 expression correlates with luminal A and B subtypes, which generally have favorable outcomes. Conversely, loss or mislocalization of CK8/18 is linked to basal-like, more aggressive phenotypes (<xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref40">40</xref>). Similarly, in canine mammary tumors, benign lesions typically maintain CK8/18 expression, while malignant tumors often exhibit reduced levels, underscoring the role of cytokeratin patterns as indicators of differentiation status (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref41">41</xref>). However, cytokeratin profiling alone does not provide comprehensive information about proliferative or mesenchymal features. Co-staining with markers such as Ki-67 for proliferation or vimentin for mesenchymal characteristics is necessary to fully characterize growth dynamics and epithelial-mesenchymal transition (<xref ref-type="bibr" rid="ref42">42</xref>). Moreover, variability in cytokeratin expression due to tissue origin, culture conditions, and passage number highlights the need for standardized protocols to ensure reproducible phenotyping across laboratories (<xref ref-type="bibr" rid="ref43">43</xref>, <xref ref-type="bibr" rid="ref44">44</xref>). Overall, the observed pan-CK and CK8/18 positivity in primary CMG cells aligns with established patterns in human and canine mammary tissues, validating these cultures as models for studying normal epithelial biology and early tumorigenic events (<xref ref-type="bibr" rid="ref45">45</xref>).</p>
<p>Immunofluorescence analysis of primary CMG cells in our study revealed strong expression of MUC1, a transmembrane glycoprotein integral to epithelial protection and signaling. In normal mammary epithelium, MUC1 is predominantly localized to the apical surface, contributing to the maintenance of cell polarity and forming a protective barrier - an indicator of a well-differentiated state (<xref ref-type="bibr" rid="ref46">46</xref>, <xref ref-type="bibr" rid="ref47">47</xref>). In malignancy, however, MUC1 expression becomes dysregulated. In human BC, MUC1 often shifts from apical to diffuse cytoplasmic or circumferential localization, correlating with loss of cell polarity, invasiveness, and poor prognosis (<xref ref-type="bibr" rid="ref48">48</xref>, <xref ref-type="bibr" rid="ref49">49</xref>). Aberrant glycosylation further enhances MUC1&#x2019;s pro-tumorigenic role, aiding in immune evasion and metastasis (<xref ref-type="bibr" rid="ref50">50</xref>). Comparable patterns are observed in canine mammary tumors, where normal tissues exhibit apical MUC1 expression, while malignant ones display cytoplasmic redistribution, linked to higher tumor grade and metastatic behavior (<xref ref-type="bibr" rid="ref51">51</xref>). In our study, CMG cells retained apical MUC1 localization consistent with non-malignant mammary epithelium, highlighting their potential as a pre-neoplastic <italic>in vitro</italic> model. This preserved epithelial phenotype makes them well-suited for investigating early alterations in MUC1 expression and function that may contribute to tumor initiation. Moreover, CMG cultures represent a promising platform for studying the mechanisms of MUC1 dysregulation in cancer progression and for preclinical evaluation of MUC1-targeted therapeutic strategies.</p>
<p>Immunofluorescence staining showed minimal Ki-67 positivity in primary CMG cells, reflecting limited proliferative activity and a predominantly quiescent cellular phenotype. Our finding aligns with the expected profile of non-malignant mammary epithelium, where Ki-67 levels are typically low due to limited mitotic activity. In contrast, elevated Ki-67 expression is a hallmark of CMTs, reflecting their higher proliferative capacity. For instance, Carvalho et al. (<xref ref-type="bibr" rid="ref52">52</xref>) reported Ki-67 indices ranging from 3 to 32% in benign tumors and 20&#x2013;49% in malignant ones, correlating with tumor aggressiveness and prognosis. Similarly, in human BC, high Ki-67 expression is associated with increased tumor grade, shorter survival, and higher recurrence risk. A meta-analysis by de Azambuja et al. (<xref ref-type="bibr" rid="ref53">53</xref>) confirmed its prognostic value in early-stage BC, demonstrating that Ki-67 positivity confers a higher risk of relapse and worse survival. Furthermore, Luporsi et al. (<xref ref-type="bibr" rid="ref54">54</xref>) emphasized the predictive relevance of Ki-67 for chemotherapy response, noting that high Ki-67 levels are associated with increased pathological complete response rates in patients undergoing neoadjuvant chemotherapy. The retention of low Ki-67 expression in CMG cultures underscores their utility as a model for studying normal proliferation and early neoplastic changes in both canine and human mammary biology. These cultures provide a relevant platform for investigating the mechanisms underlying Ki-67 dysregulation and its role in tumor progression, offering insights applicable to both veterinary and human oncology.</p>
<p>Immunofluorescence analysis of mesenchymal markers, vimentin and S100, showed negativity for both markers in CMG cells, indicating an epithelial phenotype. Vimentin is typically expressed in cells of mesenchymal origin and regulates cell growth, migration and the maintenance of cellular integrity (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref55">55</xref>). It has also been associated with cancer invasiveness and increased expression of vimentin was observed in various tumor cells and is considered a marker of epithelial-mesenchymal transition (<xref ref-type="bibr" rid="ref56">56</xref>, <xref ref-type="bibr" rid="ref57">57</xref>). Moreover, vimentin is expressed in the stromal and myoepithelial cell population of the mammary gland (<xref ref-type="bibr" rid="ref16">16</xref>, <xref ref-type="bibr" rid="ref17">17</xref>). The S100 family has many isoforms, and their expression varies by tissue and condition; S100 proteins can be found in fibroblasts, astrocytes, melanocytes, and myoepithelial cells, among others (<xref ref-type="bibr" rid="ref15">15</xref>, <xref ref-type="bibr" rid="ref58 ref59 ref60 ref61">58&#x2013;61</xref>). Overexpression of some members of S100 family has been reported in several common cancers, including breast cancer (<xref ref-type="bibr" rid="ref14">14</xref>).</p>
<p>While our findings confirm the epithelial nature and low proliferative activity of CMG cells, certain limitations should be acknowledged. Marker expression was evaluated qualitatively; quantitative techniques such as RNA <italic>in situ</italic> hybridization, as demonstrated by Li et al. (<xref ref-type="bibr" rid="ref62">62</xref>) for HER2 mRNA in canine mammary tumors, could provide more precise molecular profiling. Our marker panel was limited; inclusion of basal and myoepithelial markers (e.g., CK5, CK14, <italic>&#x03B1;</italic>-SMA, p63) would allow deeper insight into CMG cell heterogeneity, as these markers are key in distinguishing myoepithelial populations involved in tumor progression (<xref ref-type="bibr" rid="ref63 ref64 ref65">63&#x2013;65</xref>). In the present work, we deliberately focused on establishing a reference luminal epithelial culture from normal CMG tissue and therefore selected a restricted immunofluorescence panel targeting epithelial and luminal markers (pan-CK, CK8/18, MUC1) together with Ki-67 and selected mesenchymal markers (vimentin, S100). Basal/myoepithelial markers (e.g., CK5, CK14, &#x03B1;-SMA, p63) were not included because the available primary material had to be prioritized for initial luminal characterization. Moreover, the dissociation protocol and standard 2D culture conditions used here favor luminal epithelial outgrowth, whereas myoepithelial cells typically require selective enrichment and tailored media to be maintained <italic>in vitro</italic> (<xref ref-type="bibr" rid="ref29">29</xref>, <xref ref-type="bibr" rid="ref65">65</xref>, <xref ref-type="bibr" rid="ref66">66</xref>). In line with this, our cultures showed a homogeneous luminal phenotype, and we did not observe an expanding myoepithelial compartment, suggesting that myoepithelial cells from the original tissue did not efficiently proliferate or were gradually lost during early passages. Additionally, the role of MUC1 in normal versus malignant contexts requires further study. While apically localized in healthy tissue, MUC1 becomes mislocalized and aberrantly glycosylated in tumors, contributing to metastasis and immune evasion. Clarifying these functional shifts could enhance our understanding of mammary gland pathophysiology (<xref ref-type="bibr" rid="ref67">67</xref>). Future work addressing these aspects will improve the value of CMG cultures as models for mammary biology and tumorigenesis.</p>
</sec>
<sec sec-type="conclusions" id="sec18">
<label>5</label>
<title>Conclusion</title>
<p>This study is the first to successfully establish and characterize primary epithelial cell cultures directly from histologically normal CMG tissue, providing a relevant <italic>in vitro</italic> model for studying normal mammary physiology, early tumorigenesis, and supporting future development of standardized control cell lines. Histological analysis confirmed lobular structures typical of actively lactating tissue, validating the functional state of the donor gland. CMG cells adhered efficiently, reached confluence within 7&#x202F;days, and showed optimal proliferation at 4,000 cells/well, as verified by xCELLigence and XTT assays. These standardized culture conditions offer a practical reference for veterinary laboratories working in diagnostic, pharmacological, or oncological research. Immunofluorescence analysis confirmed epithelial identity (pan-CK, CK8/18), low Ki-67 expression, negative expression of mesenchymal markers (vimentin, S100) and apical MUC1 localization - features indicative of a non-malignant, differentiated phenotype. These data support the use of CMG cultures as a baseline model for distinguishing physiological epithelial characteristics from tumor-associated changes in canine mammary tissue. This model contributes to comparative oncology by enabling more accurate evaluation of tumor biology and therapeutic responses. However, limitations include the qualitative nature of marker assessment and the restricted panel used. Future work should apply quantitative techniques and include additional markers (CK5, CK14, <italic>&#x03B1;</italic>-SMA, p63), as well as investigate MUC1&#x2019;s role in canine mammary pathology. Overall, CMG cultures provide a valuable platform for translational research and the development of personalized veterinary therapies.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec19">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec20">
<title>Ethics statement</title>
<p>The animal studies were approved by Ethics committee of the UVMP in Ko&#x0161;ice (EKVP/2023&#x2013;02). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study.</p>
</sec>
<sec sec-type="author-contributions" id="sec21">
<title>Author contributions</title>
<p>NN: Writing &#x2013; review &#x0026; editing, Investigation, Writing &#x2013; original draft, Validation, Data curation, Visualization, Methodology. MH: Validation, Methodology, Software, Writing &#x2013; review &#x0026; editing. AV: Methodology, Writing &#x2013; review &#x0026; editing. LH: Methodology, Writing &#x2013; review &#x0026; editing, Investigation. BK: Validation, Methodology, Writing &#x2013; original draft. VA: Writing &#x2013; original draft, Methodology, Software, Funding acquisition, Data curation. DM: Validation, Methodology, Writing &#x2013; original draft, Investigation. PK: Writing &#x2013; original draft, Investigation, Writing &#x2013; review &#x0026; editing. SH: Writing &#x2013; review &#x0026; editing, Methodology. DC: Visualization, Funding acquisition, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft, Conceptualization.</p>
</sec>
<sec sec-type="COI-statement" id="sec22">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec23">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec24">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec25">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fvets.2025.1652991/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fvets.2025.1652991/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>T</given-names></name> <name><surname>Gama</surname><given-names>A</given-names></name> <name><surname>Seixas</surname><given-names>F</given-names></name> <name><surname>Faustino-Rocha</surname><given-names>AI</given-names></name> <name><surname>Lopes</surname><given-names>C</given-names></name> <name><surname>Gaspar</surname><given-names>VM</given-names></name> <etal/></person-group>. <article-title>Mammary glands of women, female dogs and female rats: similarities and differences to be considered in breast Cancer research</article-title>. <source>Vet Sci</source>. (<year>2023</year>) <volume>10</volume>:<fpage>379</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vetsci10060379</pub-id>, <pub-id pub-id-type="pmid">37368765</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>R</given-names></name> <name><surname>Premanandan</surname><given-names>C</given-names></name></person-group>. <source>Veterinary histology</source>. <publisher-loc>Ohio</publisher-loc>: <publisher-name>The Ohio State University</publisher-name> (<year>2017</year>).</mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abadie</surname><given-names>J</given-names></name> <name><surname>Nguyen</surname><given-names>F</given-names></name> <name><surname>Loussouarn</surname><given-names>D</given-names></name> <name><surname>Pe&#x00F1;a</surname><given-names>L</given-names></name> <name><surname>Gama</surname><given-names>A</given-names></name> <name><surname>Rieder</surname><given-names>N</given-names></name> <etal/></person-group>. <article-title>Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance</article-title>. <source>Breast Cancer Res Treat</source>. (<year>2018</year>) <volume>167</volume>:<fpage>459</fpage>&#x2013;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10549-017-4542-8</pub-id>, <pub-id pub-id-type="pmid">29063312</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jedrzejczak-Silicka</surname><given-names>M</given-names></name></person-group>. <article-title>History of cell culture</article-title> In: <person-group person-group-type="editor"><name><surname>Gowder</surname><given-names>SJ</given-names></name></person-group>, editor. <source>New insights into cell culture technology</source>. <publisher-loc>London</publisher-loc>: <publisher-name>IntechOpen</publisher-name> (<year>2017</year>)</mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>C</given-names></name> <name><surname>Kumar</surname><given-names>C</given-names></name> <name><surname>Bohl</surname><given-names>S</given-names></name> <name><surname>Klingmueller</surname><given-names>U</given-names></name> <name><surname>Mann</surname><given-names>M</given-names></name></person-group>. <article-title>Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions</article-title>. <source>Mol Cell Proteomics</source>. (<year>2009</year>) <volume>8</volume>:<fpage>443</fpage>&#x2013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1074/mcp.M800258-MCP200</pub-id>, <pub-id pub-id-type="pmid">18952599</pub-id></mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>M</given-names></name> <name><surname>Piwocka</surname><given-names>O</given-names></name> <name><surname>Musielak</surname><given-names>M</given-names></name> <name><surname>Piotrowski</surname><given-names>I</given-names></name> <name><surname>Suchorska</surname><given-names>WM</given-names></name> <name><surname>Trzeciak</surname><given-names>T</given-names></name></person-group>. <article-title>From donor to the lab: a fascinating journey of primary cell lines</article-title>. <source>Front Cell Dev Biol</source>. (<year>2021</year>) <volume>9</volume>:<fpage>381</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2021.711381</pub-id>, <pub-id pub-id-type="pmid">34395440</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Faria Lainetti</surname><given-names>P</given-names></name> <name><surname>Brandi</surname><given-names>A</given-names></name> <name><surname>Leis Filho</surname><given-names>AF</given-names></name> <name><surname>Prado</surname><given-names>MCM</given-names></name> <name><surname>Kobayashi</surname><given-names>PE</given-names></name> <name><surname>Laufer-Amorim</surname><given-names>R</given-names></name> <etal/></person-group>. <article-title>Establishment and characterization of canine mammary gland carcinoma cell lines with vasculogenic mimicry ability in vitro and in vivo</article-title>. <source>Front Vet Sci</source>. (<year>2020</year>) <volume>7</volume>:<fpage>583874</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fvets.2020.583874</pub-id>, <pub-id pub-id-type="pmid">33195606</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inman</surname><given-names>JL</given-names></name> <name><surname>Robertson</surname><given-names>C</given-names></name> <name><surname>Mott</surname><given-names>JD</given-names></name> <name><surname>Bissell</surname><given-names>MJ</given-names></name></person-group>. <article-title>Mammary gland development: cell fate specification, stem cells and the microenvironment</article-title>. <source>Development</source>. (<year>2015</year>) <volume>142</volume>:<fpage>1028</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dev.087643</pub-id>, <pub-id pub-id-type="pmid">25758218</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>IH</given-names></name> <name><surname>Russo</surname><given-names>J</given-names></name></person-group>. <article-title>Mammary gland neoplasia in long-term rodent studies</article-title>. <source>Environ Health Perspect</source>. (<year>1996</year>) <volume>104</volume>:<fpage>938</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1289/ehp.96104938</pub-id>, <pub-id pub-id-type="pmid">8899375</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanowicz-Hajduk</surname><given-names>J</given-names></name> <name><surname>Ochocka</surname><given-names>JR</given-names></name></person-group>. <article-title>Real-time cell analysis system in cytotoxicity applications: usefulness and comparison with tetrazolium salt assays</article-title>. <source>Toxicol Rep</source>. (<year>2020</year>) <volume>7</volume>:<fpage>335</fpage>&#x2013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.toxrep.2020.02.002</pub-id>, <pub-id pub-id-type="pmid">32090021</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javed</surname><given-names>A</given-names></name> <name><surname>Lteif</surname><given-names>A</given-names></name></person-group>. <article-title>Development of the human breast</article-title>. <source>Semin Plast Surg</source>. (<year>2013</year>) <volume>27</volume>:<fpage>005</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0033-1343989</pub-id>, <pub-id pub-id-type="pmid">24872732</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miron-Mendoza</surname><given-names>M</given-names></name> <name><surname>Poole</surname><given-names>K</given-names></name> <name><surname>DiCesare</surname><given-names>S</given-names></name> <name><surname>Nakahara</surname><given-names>E</given-names></name> <name><surname>Bhatt</surname><given-names>MP</given-names></name> <name><surname>Hulleman</surname><given-names>JD</given-names></name> <etal/></person-group>. <article-title>The role of vimentin in human corneal fibroblast spreading and myofibroblast transformation</article-title>. <source>Cells</source>. (<year>2024</year>) <volume>13</volume>:<fpage>1094</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells13131094</pub-id>, <pub-id pub-id-type="pmid">38994947</pub-id></mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>DB</given-names></name> <name><surname>Cornwall</surname><given-names>EH</given-names></name> <name><surname>Landar</surname><given-names>A</given-names></name> <name><surname>Song</surname><given-names>W</given-names></name></person-group>. <article-title>The S100 protein family: history, function, and expression</article-title>. <source>Brain Res Bull</source>. (<year>1995</year>) <volume>37</volume>:<fpage>417</fpage>&#x2013;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0361-9230(95)00040-2</pub-id>, <pub-id pub-id-type="pmid">7620916</pub-id></mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>SS</given-names></name> <name><surname>Hamdy</surname><given-names>FC</given-names></name> <name><surname>Deloulme</surname><given-names>JC</given-names></name> <name><surname>Rehman</surname><given-names>I</given-names></name></person-group>. <article-title>Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers</article-title>. <source>Histopathology</source>. (<year>2005</year>) <volume>46</volume>:<fpage>256</fpage>&#x2013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2559.2005.02097.x</pub-id>, <pub-id pub-id-type="pmid">15720411</pub-id></mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomcik</surname><given-names>M</given-names></name> <name><surname>Palumbo-Zerr</surname><given-names>K</given-names></name> <name><surname>Zerr</surname><given-names>P</given-names></name> <name><surname>Avouac</surname><given-names>J</given-names></name> <name><surname>Dees</surname><given-names>C</given-names></name> <name><surname>Sumova</surname><given-names>B</given-names></name> <etal/></person-group>. <article-title>S100A4 amplifies TGF-&#x03B2;-induced fibroblast activation in systemic sclerosis</article-title>. <source>Ann Rheum Dis</source>. (<year>2015</year>) <volume>74</volume>:<fpage>1748</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204516</pub-id>, <pub-id pub-id-type="pmid">24709861</pub-id></mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peuhu</surname><given-names>E</given-names></name> <name><surname>Virtakoivu</surname><given-names>R</given-names></name> <name><surname>Mai</surname><given-names>A</given-names></name> <name><surname>W&#x00E4;rri</surname><given-names>A</given-names></name> <name><surname>Ivaska</surname><given-names>J</given-names></name></person-group>. <article-title>Epithelial vimentin plays a functional role in mammary gland development</article-title>. <source>Development</source>. (<year>2017</year>) <volume>144</volume>:<fpage>4103</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dev.154229</pub-id>, <pub-id pub-id-type="pmid">28947532</pub-id></mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finot</surname><given-names>L</given-names></name> <name><surname>Chanat</surname><given-names>E</given-names></name> <name><surname>Dessauge</surname><given-names>F</given-names></name></person-group>. <article-title>Molecular signature of the putative stem/progenitor cells committed to the development of the bovine mammary gland at puberty</article-title>. <source>Sci Rep</source>. (<year>2018</year>) <volume>8</volume>:<fpage>16194</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-34691-2</pub-id>, <pub-id pub-id-type="pmid">30385815</pub-id></mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>YS</given-names></name> <name><surname>Fakoya</surname><given-names>AO</given-names></name> <name><surname>Sajjad</surname><given-names>H</given-names></name></person-group>. <source>Anatomy, thorax: mammary gland</source>. <publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name> (<year>2025</year>).</mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>SK</given-names></name> <name><surname>Banerjee</surname><given-names>S</given-names></name> <name><surname>Baker</surname><given-names>GW</given-names></name> <name><surname>Kuo</surname><given-names>C-Y</given-names></name> <name><surname>Chowdhury</surname><given-names>I</given-names></name></person-group>. <article-title>The mammary gland: basic structure and molecular Signaling during development</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>:<fpage>3883</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms23073883</pub-id>, <pub-id pub-id-type="pmid">35409243</pub-id></mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macias</surname><given-names>H</given-names></name> <name><surname>Hinck</surname><given-names>L</given-names></name></person-group>. <article-title>Mammary gland development</article-title>. <source>Wiley Interdiscip Rev Dev Biol</source>. (<year>2012</year>) <volume>1</volume>:<fpage>533</fpage>&#x2013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1002/wdev.35</pub-id>, <pub-id pub-id-type="pmid">22844349</pub-id></mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakes</surname><given-names>SR</given-names></name> <name><surname>Rogers</surname><given-names>RL</given-names></name> <name><surname>Naylor</surname><given-names>MJ</given-names></name> <name><surname>Ormandy</surname><given-names>CJ</given-names></name></person-group>. <article-title>Prolactin regulation of mammary gland development</article-title>. <source>J Mammary Gland Biol Neoplasia</source>. (<year>2008</year>) <volume>13</volume>:<fpage>13</fpage>&#x2013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10911-008-9069-5</pub-id>, <pub-id pub-id-type="pmid">18219564</pub-id></mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monks</surname><given-names>NR</given-names></name> <name><surname>Cherba</surname><given-names>DM</given-names></name> <name><surname>Kamerling</surname><given-names>SG</given-names></name> <name><surname>Simpson</surname><given-names>H</given-names></name> <name><surname>Rusk</surname><given-names>AW</given-names></name> <name><surname>Carter</surname><given-names>D</given-names></name> <etal/></person-group>. <article-title>A multi-site feasibility study for personalized medicine in canines with osteosarcoma</article-title>. <source>J Transl Med</source>. (<year>2013</year>) <volume>11</volume>:<fpage>158</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1479-5876-11-158</pub-id>, <pub-id pub-id-type="pmid">23815880</pub-id></mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorenmo</surname><given-names>KU</given-names></name> <name><surname>Rasotto</surname><given-names>R</given-names></name> <name><surname>Zappulli</surname><given-names>V</given-names></name> <name><surname>Goldschmidt</surname><given-names>MH</given-names></name></person-group>. <article-title>Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms</article-title>. <source>Vet Pathol</source>. (<year>2011</year>) <volume>48</volume>:<fpage>85</fpage>&#x2013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0300985810389480</pub-id>, <pub-id pub-id-type="pmid">21147765</pub-id></mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>CJ</given-names></name></person-group>. <article-title>Key stages in mammary gland development - involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ</article-title>. <source>Breast Cancer Res</source>. (<year>2006</year>) <volume>8</volume>:<fpage>203</fpage>. doi: <pub-id pub-id-type="doi">10.1186/bcr1401</pub-id>, <pub-id pub-id-type="pmid">16677411</pub-id></mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moe</surname><given-names>L</given-names></name></person-group>. <article-title>Population-based incidence of mammary tumours in some dog breeds</article-title>. <source>J Reprod Fertil Suppl</source>. (<year>2001</year>) <volume>57</volume>:<fpage>439</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="pmid">11787188</pub-id></mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vilhena</surname><given-names>H</given-names></name> <name><surname>Figueira</surname><given-names>AC</given-names></name> <name><surname>Schmitt</surname><given-names>F</given-names></name> <name><surname>Canadas</surname><given-names>A</given-names></name> <name><surname>Chaves</surname><given-names>R</given-names></name> <name><surname>Gama</surname><given-names>A</given-names></name> <etal/></person-group>. <article-title>Canine and feline spontaneous mammary tumours as models of human breast Cancer</article-title> In: <person-group person-group-type="editor"><name><surname>Pastorinho</surname><given-names>MR</given-names></name> <name><surname>Sousa</surname><given-names>ACA</given-names></name></person-group>, editors. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name> (<year>2020</year>). <fpage>173</fpage>&#x2013;<lpage>207</lpage>.</mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>&#x0141;</given-names></name> <name><surname>Krajewski</surname><given-names>W</given-names></name> <name><surname>Ma&#x0142;kiewicz</surname><given-names>B</given-names></name> <name><surname>Szyde&#x0142;ko</surname><given-names>T</given-names></name> <name><surname>Pawlak</surname><given-names>A</given-names></name></person-group>. <article-title>Characteristics and applications of canine in vitro models of bladder Cancer in veterinary medicine: an up-to-date Mini review</article-title>. <source>Animals</source>. (<year>2022</year>) <volume>12</volume>:<fpage>516</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ani12040516</pub-id>, <pub-id pub-id-type="pmid">35203224</pub-id></mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilsky</surname><given-names>RL</given-names></name></person-group>. <article-title>Personalized medicine in oncology: the future is now</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2010</year>) <volume>9</volume>:<fpage>363</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrd3181</pub-id>, <pub-id pub-id-type="pmid">20431568</pub-id></mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x00E1;nchez-C&#x00E9;spedes</surname><given-names>R</given-names></name> <name><surname>Maniscalco</surname><given-names>L</given-names></name> <name><surname>Iussich</surname><given-names>S</given-names></name> <name><surname>Martignani</surname><given-names>E</given-names></name> <name><surname>Guil-Luna</surname><given-names>S</given-names></name> <name><surname>De Maria</surname><given-names>R</given-names></name> <etal/></person-group>. <article-title>Isolation, purification, culture and characterisation of myoepithelial cells from normal and neoplastic canine mammary glands using a magnetic-activated cell sorting separation system</article-title>. <source>Vet J</source>. (<year>2013</year>) <volume>197</volume>:<fpage>474</fpage>&#x2013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tvjl.2013.03.005</pub-id>, <pub-id pub-id-type="pmid">23583698</pub-id></mixed-citation></ref>
<ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocola</surname><given-names>C</given-names></name> <name><surname>Anastasi</surname><given-names>P</given-names></name> <name><surname>Astigiano</surname><given-names>S</given-names></name> <name><surname>Piscitelli</surname><given-names>E</given-names></name> <name><surname>Pelucchi</surname><given-names>P</given-names></name> <name><surname>Vilardo</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>Isolation of canine mammary cells with stem cell properties and tumour-initiating potential</article-title>. <source>Reprod Domest Anim</source>. (<year>2009</year>) <volume>44</volume>:<fpage>214</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1439-0531.2009.01413.x</pub-id>, <pub-id pub-id-type="pmid">19754572</pub-id></mixed-citation></ref>
<ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrou&#x0161;kova</surname><given-names>P</given-names></name> <name><surname>Hud&#x00E1;kov&#x00E1;</surname><given-names>N</given-names></name> <name><surname>Alm&#x00E1;&#x0161;iov&#x00E1;</surname><given-names>V</given-names></name> <name><surname>Valen&#x010D;&#x00E1;kov&#x00E1;</surname><given-names>A</given-names></name> <name><surname>Hor&#x0148;&#x00E1;kov&#x00E1;</surname><given-names>L</given-names></name> <name><surname>Huniadi</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>Establishment of primary cell cultures from canine mammary gland malignant tumours: a preliminary study</article-title>. <source>J Vet Res</source>. (<year>2025</year>) <volume>69</volume>:<fpage>159</fpage>&#x2013;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.2478/jvetres-2025-0007</pub-id>, <pub-id pub-id-type="pmid">40144054</pub-id></mixed-citation></ref>
<ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamani-Ahmadmahmudi</surname><given-names>M</given-names></name> <name><surname>Nassiri</surname><given-names>SM</given-names></name> <name><surname>Jahanzad</surname><given-names>I</given-names></name> <name><surname>Shirani</surname><given-names>D</given-names></name> <name><surname>Rahbarghazi</surname><given-names>R</given-names></name> <name><surname>Yazdani</surname><given-names>B</given-names></name></person-group>. <article-title>Isolation and characterization of a canine mammary cell line prepared for proteomics analysis</article-title>. <source>Tissue Cell</source>. (<year>2013</year>) <volume>45</volume>:<fpage>183</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tice.2012.11.002</pub-id>, <pub-id pub-id-type="pmid">23375365</pub-id></mixed-citation></ref>
<ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardicli</surname><given-names>S</given-names></name> <name><surname>Samli</surname><given-names>H</given-names></name> <name><surname>Mecitoglu</surname><given-names>G</given-names></name> <name><surname>Vatansever</surname><given-names>B</given-names></name> <name><surname>Mutlu</surname><given-names>AM</given-names></name></person-group>. <article-title>The establishment of primary cell culture from canine mammary gland tumor</article-title>. <source>J Cell Biotechnol</source>. (<year>2021</year>) <volume>7</volume>:<fpage>57</fpage>&#x2013;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JCB-210036</pub-id></mixed-citation></ref>
<ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orfanou</surname><given-names>DC</given-names></name> <name><surname>Pourlis</surname><given-names>A</given-names></name> <name><surname>Ververidis</surname><given-names>HN</given-names></name> <name><surname>Mavrogianni</surname><given-names>VS</given-names></name> <name><surname>Taitzoglou</surname><given-names>IA</given-names></name> <name><surname>Boscos</surname><given-names>CM</given-names></name> <etal/></person-group>. <article-title>Histological features in the mammary glands of female dogs throughout lactation</article-title>. <source>Anat Histol Embryol</source>. (<year>2010</year>) <volume>39</volume>:<fpage>473</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1439-0264.2010.01018.x</pub-id>, <pub-id pub-id-type="pmid">20633001</pub-id></mixed-citation></ref>
<ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caceres</surname><given-names>S</given-names></name> <name><surname>Pe&#x00F1;a</surname><given-names>L</given-names></name> <name><surname>de Andres</surname><given-names>PJ</given-names></name> <name><surname>Illera</surname><given-names>MJ</given-names></name> <name><surname>Lopez</surname><given-names>MS</given-names></name> <name><surname>Woodward</surname><given-names>WA</given-names></name> <etal/></person-group>. <article-title>Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366</article-title>. <source>PLoS One</source>. (<year>2015</year>) <volume>10</volume>:<fpage>e0122277</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0122277</pub-id>, <pub-id pub-id-type="pmid">25807360</pub-id></mixed-citation></ref>
<ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barak</surname><given-names>V</given-names></name> <name><surname>Goike</surname><given-names>H</given-names></name> <name><surname>Panaretakis</surname><given-names>KW</given-names></name> <name><surname>Einarsson</surname><given-names>R</given-names></name></person-group>. <article-title>Clinical utility of cytokeratins as tumor markers</article-title>. <source>Clin Biochem</source>. (<year>2004</year>) <volume>37</volume>:<fpage>529</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2004.05.009</pub-id>, <pub-id pub-id-type="pmid">15234234</pub-id></mixed-citation></ref>
<ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menz</surname><given-names>A</given-names></name> <name><surname>Gorbokon</surname><given-names>N</given-names></name> <name><surname>Viehweger</surname><given-names>F</given-names></name> <name><surname>Lennartz</surname><given-names>M</given-names></name> <name><surname>Hube-Magg</surname><given-names>C</given-names></name> <name><surname>Hornsteiner</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>Pan-keratin immunostaining in human Tumors: a tissue microarray study of 15,940 Tumors</article-title>. <source>Int J Surg Pathol</source>. (<year>2023</year>) <volume>31</volume>:<fpage>927</fpage>&#x2013;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.1177/10668969221117243</pub-id>, <pub-id pub-id-type="pmid">35946088</pub-id></mixed-citation></ref>
<ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd El-Rehim</surname><given-names>DM</given-names></name> <name><surname>Pinder</surname><given-names>SE</given-names></name> <name><surname>Paish</surname><given-names>CE</given-names></name> <name><surname>Bell</surname><given-names>J</given-names></name> <name><surname>Blamey</surname><given-names>RW</given-names></name> <name><surname>Robertson</surname><given-names>JFR</given-names></name> <etal/></person-group>. <article-title>Expression of luminal and basal cytokeratins in human breast carcinoma</article-title>. <source>J Pathol</source>. (<year>2004</year>) <volume>203</volume>:<fpage>661</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1002/path.1559</pub-id>, <pub-id pub-id-type="pmid">15141381</pub-id></mixed-citation></ref>
<ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiad</surname><given-names>HA</given-names></name> <name><surname>Samaka</surname><given-names>RM</given-names></name> <name><surname>Asaad</surname><given-names>NY</given-names></name> <name><surname>Kandil</surname><given-names>MA</given-names></name> <name><surname>Shehata</surname><given-names>MA</given-names></name> <name><surname>Miligy</surname><given-names>IM</given-names></name></person-group>. <article-title>Relationship of CK8/18 expression pattern to breast cancer immunohistochemical subtyping in Egyptian patients</article-title>. <source>Ecancermedicalscience</source>. (<year>2014</year>) <volume>8</volume>:<fpage>404</fpage>. doi: <pub-id pub-id-type="doi">10.3332/ecancer.2014.404</pub-id>, <pub-id pub-id-type="pmid">24605136</pub-id></mixed-citation></ref>
<ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amirkhani Namagerdi</surname><given-names>A</given-names></name> <name><surname>d&#x2019;Angelo</surname><given-names>D</given-names></name> <name><surname>Ciani</surname><given-names>F</given-names></name> <name><surname>Iannuzzi</surname><given-names>CA</given-names></name> <name><surname>Napolitano</surname><given-names>F</given-names></name> <name><surname>Avallone</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>Triple-negative breast Cancer comparison with canine mammary Tumors from light microscopy to molecular pathology</article-title>. <source>Front Oncol</source>. (<year>2020</year>) <volume>10</volume>:<fpage>563779</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2020.563779</pub-id>, <pub-id pub-id-type="pmid">33282730</pub-id></mixed-citation></ref>
<ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fhaikrue</surname><given-names>I</given-names></name> <name><surname>Srisawat</surname><given-names>W</given-names></name> <name><surname>Nambooppha</surname><given-names>B</given-names></name> <name><surname>Pringproa</surname><given-names>K</given-names></name> <name><surname>Thongtharb</surname><given-names>A</given-names></name> <name><surname>Prachasilchai</surname><given-names>W</given-names></name> <etal/></person-group>. <article-title>Identification of potential canine mammary tumour cell biomarkers using proteomic approach: differences in protein profiles among tumour and normal mammary epithelial cells by two-dimensional electrophoresis-based mass spectrometry</article-title>. <source>Vet Comp Oncol</source>. (<year>2020</year>) <volume>18</volume>:<fpage>787</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1111/vco.12610</pub-id>, <pub-id pub-id-type="pmid">32421920</pub-id></mixed-citation></ref>
<ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sammarco</surname><given-names>A</given-names></name> <name><surname>Gomiero</surname><given-names>C</given-names></name> <name><surname>Beffagna</surname><given-names>G</given-names></name> <name><surname>Cavicchioli</surname><given-names>L</given-names></name> <name><surname>Ferro</surname><given-names>S</given-names></name> <name><surname>Michieletto</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Epithelial-to-mesenchymal transition and phenotypic marker evaluation in human, canine, and feline mammary gland Tumors</article-title>. <source>Animals (Basel)</source>. (<year>2023</year>) <volume>13</volume>:<fpage>878</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ani13050878</pub-id>, <pub-id pub-id-type="pmid">36899736</pub-id></mixed-citation></ref>
<ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paladino</surname><given-names>G</given-names></name> <name><surname>Marino</surname><given-names>C</given-names></name> <name><surname>La Terra</surname><given-names>MS</given-names></name> <name><surname>Civiale</surname><given-names>C</given-names></name> <name><surname>Rusciano</surname><given-names>D</given-names></name> <name><surname>Enea</surname><given-names>V</given-names></name></person-group>. <article-title>Cytokeratin expression in primary epithelial cell culture from bovine conjunctiva</article-title>. <source>Tissue Cell</source>. (<year>2004</year>) <volume>36</volume>:<fpage>323</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tice.2004.05.003</pub-id>, <pub-id pub-id-type="pmid">15385149</pub-id></mixed-citation></ref>
<ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidney</surname><given-names>LE</given-names></name> <name><surname>McIntosh</surname><given-names>OD</given-names></name> <name><surname>Hopkinson</surname><given-names>A</given-names></name></person-group>. <article-title>Phenotypic change and induction of cytokeratin expression during in vitro culture of corneal stromal cells</article-title>. <source>Invest Ophthalmol Vis Sci</source>. (<year>2015</year>) <volume>56</volume>:<fpage>7225</fpage>&#x2013;<lpage>35</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.15-17810</pub-id>, <pub-id pub-id-type="pmid">26544791</pub-id></mixed-citation></ref>
<ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakes</surname><given-names>SR</given-names></name> <name><surname>Gallego-Ortega</surname><given-names>D</given-names></name> <name><surname>Ormandy</surname><given-names>CJ</given-names></name></person-group>. <article-title>The mammary cellular hierarchy and breast cancer</article-title>. <source>Cell Mol Life Sci</source>. (<year>2014</year>) <volume>71</volume>:<fpage>4301</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-014-1674-4</pub-id>, <pub-id pub-id-type="pmid">25080108</pub-id></mixed-citation></ref>
<ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brayman</surname><given-names>M</given-names></name> <name><surname>Thathiah</surname><given-names>A</given-names></name> <name><surname>Carson</surname><given-names>DD</given-names></name></person-group>. <article-title>MUC1: a multifunctional cell surface component of reproductive tissue epithelia</article-title>. <source>Reprod Biol Endocrinol</source>. (<year>2004</year>) <volume>2</volume>:<fpage>4</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1477-7827-2-4</pub-id>, <pub-id pub-id-type="pmid">14711375</pub-id></mixed-citation></ref>
<ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semba</surname><given-names>R</given-names></name> <name><surname>Horimoto</surname><given-names>Y</given-names></name> <name><surname>Sakata-Matsuzawa</surname><given-names>M</given-names></name> <name><surname>Ishizuka</surname><given-names>Y</given-names></name> <name><surname>Denda-Nagai</surname><given-names>K</given-names></name> <name><surname>Fujihira</surname><given-names>H</given-names></name> <etal/></person-group>. <article-title>Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>5281</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-32579-4</pub-id>, <pub-id pub-id-type="pmid">37002293</pub-id></mixed-citation></ref>
<ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>S</given-names></name> <name><surname>Kumar</surname><given-names>S</given-names></name> <name><surname>Choudhury</surname><given-names>A</given-names></name> <name><surname>Ponnusamy</surname><given-names>MP</given-names></name> <name><surname>Batra</surname><given-names>SK</given-names></name></person-group>. <article-title>Altered mucins (MUC) trafficking in benign and malignant conditions</article-title>. <source>Oncotarget</source>. (<year>2014</year>) <volume>5</volume>:<fpage>7272</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.2370</pub-id>, <pub-id pub-id-type="pmid">25261375</pub-id></mixed-citation></ref>
<ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name> <name><surname>Chu</surname><given-names>Y</given-names></name> <name><surname>Li</surname><given-names>S</given-names></name> <name><surname>Yu</surname><given-names>L</given-names></name> <name><surname>Deng</surname><given-names>H</given-names></name> <name><surname>Liao</surname><given-names>C</given-names></name> <etal/></person-group>. <article-title>The oncoprotein MUC1 facilitates breast cancer progression by promoting Pink1-dependent mitophagy via ATAD3A destabilization</article-title>. <source>Cell Death Dis</source>. (<year>2022</year>) <volume>13</volume>:<fpage>899</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-022-05345-z</pub-id>, <pub-id pub-id-type="pmid">36289190</pub-id></mixed-citation></ref>
<ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name> <name><surname>Sandrine</surname><given-names>IK</given-names></name> <name><surname>Yang</surname><given-names>M</given-names></name> <name><surname>Tu</surname><given-names>J</given-names></name> <name><surname>Yuan</surname><given-names>X</given-names></name></person-group>. <article-title>MUC1 and MUC16: critical for immune modulation in cancer therapeutics</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<fpage>913</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2024.1356913</pub-id>, <pub-id pub-id-type="pmid">38361923</pub-id></mixed-citation></ref>
<ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>JT</given-names></name> <name><surname>Pinho</surname><given-names>SS</given-names></name> <name><surname>de Matos</surname><given-names>AJ</given-names></name> <name><surname>Hespanhol</surname><given-names>V</given-names></name> <name><surname>Reis</surname><given-names>CA</given-names></name> <name><surname>G&#x00E4;rtner</surname><given-names>F</given-names></name></person-group>. <article-title>MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features</article-title>. <source>Vet J</source>. (<year>2009</year>) <volume>182</volume>:<fpage>491</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tvjl.2008.09.007</pub-id>, <pub-id pub-id-type="pmid">18948041</pub-id></mixed-citation></ref>
<ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>MI</given-names></name> <name><surname>Pires</surname><given-names>I</given-names></name> <name><surname>Prada</surname><given-names>J</given-names></name> <name><surname>Lobo</surname><given-names>L</given-names></name> <name><surname>Queiroga</surname><given-names>FL</given-names></name></person-group>. <article-title>Ki-67 and PCNA expression in canine mammary Tumors and adjacent nonneoplastic mammary glands: prognostic impact by a multivariate survival analysis</article-title>. <source>Vet Pathol</source>. (<year>2016</year>) <volume>53</volume>:<fpage>1138</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0300985816646429</pub-id>, <pub-id pub-id-type="pmid">27162119</pub-id></mixed-citation></ref>
<ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Azambuja</surname><given-names>E</given-names></name> <name><surname>Cardoso</surname><given-names>F</given-names></name> <name><surname>de Castro</surname><given-names>G</given-names></name> <name><surname>Colozza</surname><given-names>M</given-names></name> <name><surname>Mano</surname><given-names>MS</given-names></name> <name><surname>Durbecq</surname><given-names>V</given-names></name> <etal/></person-group>. <article-title>Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients</article-title>. <source>Br J Cancer</source>. (<year>2007</year>) <volume>96</volume>:<fpage>1504</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.bjc.6603756</pub-id>, <pub-id pub-id-type="pmid">17453008</pub-id></mixed-citation></ref>
<ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luporsi</surname><given-names>E</given-names></name> <name><surname>Andr&#x00E9;</surname><given-names>F</given-names></name> <name><surname>Spyratos</surname><given-names>F</given-names></name> <name><surname>Martin</surname><given-names>P-M</given-names></name> <name><surname>Jacquemier</surname><given-names>J</given-names></name> <name><surname>Penault-Llorca</surname><given-names>F</given-names></name> <etal/></person-group>. <article-title>Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review</article-title>. <source>Breast Cancer Res Treat</source>. (<year>2012</year>) <volume>132</volume>:<fpage>895</fpage>&#x2013;<lpage>915</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10549-011-1837-z</pub-id>, <pub-id pub-id-type="pmid">22048814</pub-id></mixed-citation></ref>
<ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surolia</surname><given-names>R</given-names></name> <name><surname>Li</surname><given-names>FJ</given-names></name> <name><surname>Wang</surname><given-names>Z</given-names></name> <name><surname>Li</surname><given-names>H</given-names></name> <name><surname>Dsouza</surname><given-names>K</given-names></name> <name><surname>Thomas</surname><given-names>V</given-names></name> <etal/></person-group>. <article-title>Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury</article-title>. <source>JCI Insight</source>. (<year>2019</year>) <volume>4</volume>:<fpage>e123253</fpage>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.123253</pub-id>, <pub-id pub-id-type="pmid">30944258</pub-id></mixed-citation></ref>
<ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>N</given-names></name> <name><surname>Tokunaga</surname><given-names>E</given-names></name> <name><surname>Kitao</surname><given-names>H</given-names></name> <name><surname>Hisamatsu</surname><given-names>Y</given-names></name> <name><surname>Taketani</surname><given-names>K</given-names></name> <name><surname>Akiyoshi</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Vimentin as a poor prognostic factor for triple-negative breast cancer</article-title>. <source>J Cancer Res Clin Oncol</source>. (<year>2013</year>) <volume>139</volume>:<fpage>739</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00432-013-1376-6</pub-id>, <pub-id pub-id-type="pmid">23354842</pub-id></mixed-citation></ref>
<ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkinos</surname><given-names>MI</given-names></name> <name><surname>Wafai</surname><given-names>R</given-names></name> <name><surname>Wong</surname><given-names>MK</given-names></name> <name><surname>Newgreen</surname><given-names>DF</given-names></name> <name><surname>Thompson</surname><given-names>EW</given-names></name> <name><surname>Waltham</surname><given-names>M</given-names></name></person-group>. <article-title>Vimentin and epithelial-mesenchymal transition in human breast Cancer &#x2013; observations in vitro and in vivo</article-title>. <source>Cells Tissues Organs</source>. (<year>2007</year>) <volume>185</volume>:<fpage>191</fpage>&#x2013;<lpage>203</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000101320</pub-id>, <pub-id pub-id-type="pmid">17587825</pub-id></mixed-citation></ref>
<ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name> <name><surname>Yi</surname><given-names>M</given-names></name> <name><surname>Zhou</surname><given-names>F</given-names></name> <name><surname>He</surname><given-names>W</given-names></name> <name><surname>Yang</surname><given-names>A</given-names></name> <name><surname>Qiu</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>S100B is selectively expressed by gray matter protoplasmic astrocytes and myelinating oligodendrocytes in the developing CNS</article-title>. <source>Mol Brain</source>. (<year>2021</year>) <volume>14</volume>:<fpage>154</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13041-021-00865-9</pub-id>, <pub-id pub-id-type="pmid">34615523</pub-id></mixed-citation></ref>
<ref id="ref59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersson</surname><given-names>S</given-names></name> <name><surname>Shubbar</surname><given-names>E</given-names></name> <name><surname>Enerb&#x00E4;ck</surname><given-names>L</given-names></name> <name><surname>Enerb&#x00E4;ck</surname><given-names>C</given-names></name></person-group>. <article-title>Expression patterns of S100 proteins in melanocytes and melanocytic lesions</article-title>. <source>Melanoma Res</source>. (<year>2009</year>) <volume>19</volume>:<fpage>215</fpage>&#x2013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CMR.0b013e32832c6358</pub-id>, <pub-id pub-id-type="pmid">19521263</pub-id></mixed-citation></ref>
<ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudier</surname><given-names>J</given-names></name> <name><surname>Gentil</surname><given-names>BJ</given-names></name></person-group>. <article-title>The S100B protein and Partners in Adipocyte Response to cold stress and adaptive thermogenesis: facts, hypotheses, and perspectives</article-title>. <source>Biomolecules</source>. (<year>2020</year>) <volume>10</volume>:<fpage>843</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom10060843</pub-id>, <pub-id pub-id-type="pmid">32486507</pub-id></mixed-citation></ref>
<ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popnikolov</surname><given-names>NK</given-names></name> <name><surname>Ayala</surname><given-names>AG</given-names></name> <name><surname>Graves</surname><given-names>K</given-names></name> <name><surname>Gatalica</surname><given-names>Z</given-names></name></person-group>. <article-title>Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas</article-title>. <source>Am J Clin Pathol</source>. (<year>2003</year>) <volume>120</volume>:<fpage>161</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1309/G6CT-R8MD-TFUW-19XV</pub-id>, <pub-id pub-id-type="pmid">12931544</pub-id></mixed-citation></ref>
<ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name> <name><surname>Wu</surname><given-names>H</given-names></name> <name><surname>Sun</surname><given-names>Y</given-names></name> <name><surname>Zhu</surname><given-names>J</given-names></name> <name><surname>Tang</surname><given-names>J</given-names></name> <name><surname>Kuang</surname><given-names>Y</given-names></name> <etal/></person-group>. <article-title>A novel canine mammary Cancer cell line: preliminary identification and utilization for drug screening studies</article-title>. <source>Front Vet Sci</source>. (<year>2021</year>) <volume>8</volume>:<fpage>906</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fvets.2021.665906</pub-id>, <pub-id pub-id-type="pmid">34124226</pub-id></mixed-citation></ref>
<ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deckwirth</surname><given-names>V</given-names></name> <name><surname>Rajakyl&#x00E4;</surname><given-names>EK</given-names></name> <name><surname>Cattavarayane</surname><given-names>S</given-names></name> <name><surname>Acheva</surname><given-names>A</given-names></name> <name><surname>Schaible</surname><given-names>N</given-names></name> <name><surname>Krishnan</surname><given-names>R</given-names></name> <etal/></person-group>. <article-title>Cytokeratin 5 determines maturation of the mammary myoepithelium</article-title>. <source>iScience</source>. (<year>2021</year>) <volume>24</volume>:<fpage>102413</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.isci.2021.102413</pub-id>, <pub-id pub-id-type="pmid">34007958</pub-id></mixed-citation></ref>
<ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x00E4;rtner</surname><given-names>F</given-names></name></person-group>. <article-title>p63: a novel myoepithelial cell marker in canine mammary tissues</article-title>. <source>Vet Pathol</source>. (<year>2003</year>) <volume>40</volume>:<fpage>412</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1354/VP.40-4-412</pub-id>, <pub-id pub-id-type="pmid">12824513</pub-id></mixed-citation></ref>
<ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x00E1;nchez-C&#x00E9;spedes</surname><given-names>R</given-names></name> <name><surname>Mill&#x00E1;n</surname><given-names>Y</given-names></name> <name><surname>Guil-Luna</surname><given-names>S</given-names></name> <name><surname>Reymundo</surname><given-names>C</given-names></name> <name><surname>de Espinosa los Monteros</surname><given-names>A</given-names></name> <name><surname>Mart&#x00ED;n las Mulas</surname><given-names>J</given-names></name></person-group>. <article-title>Myoepithelial cells in canine mammary tumours</article-title>. <source>Vet J</source>. (<year>2016</year>) <volume>207</volume>:<fpage>45</fpage>&#x2013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tvjl.2015.10.035</pub-id>, <pub-id pub-id-type="pmid">26639832</pub-id></mixed-citation></ref>
<ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zubeldia-Plazaola</surname><given-names>A</given-names></name> <name><surname>Ametller</surname><given-names>E</given-names></name> <name><surname>Mancino</surname><given-names>M</given-names></name> <name><surname>de Prats Puig</surname><given-names>M</given-names></name> <name><surname>L&#x00F3;pez-Plana</surname><given-names>A</given-names></name> <name><surname>Guzman</surname><given-names>F</given-names></name> <etal/></person-group>. <article-title>Comparison of methods for the isolation of human breast epithelial and myoepithelial cells</article-title>. <source>Front Cell Dev Biol</source>. (<year>2015</year>) <volume>3</volume>:<fpage>32</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2015.00032</pub-id>, <pub-id pub-id-type="pmid">26052514</pub-id></mixed-citation></ref>
<ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajakyl&#x00E4;</surname><given-names>K</given-names></name> <name><surname>Krishnan</surname><given-names>R</given-names></name> <name><surname>Tojkander</surname><given-names>S</given-names></name></person-group>. <article-title>Analysis of contractility and invasion potential of two canine mammary tumor cell lines</article-title>. <source>Front Vet Sci</source>. (<year>2017</year>) <volume>4</volume>:<fpage>149</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fvets.2017.00149</pub-id>, <pub-id pub-id-type="pmid">28955712</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001"><p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/668529/overview">Carlos Eduardo Fonseca-Alves</ext-link>, Paulista University, Brazil</p></fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002"><p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/71457/overview">Valeria Grieco</ext-link>, University of Milan, Italy</p><p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/469889/overview">Pedro Luiz Porfirio Xavier</ext-link>, University of S&#x00E3;o Paulo, Brazil</p></fn>
</fn-group>
</back>
</article>